^
    1d
    SZ4601: CAR-T Cell Therapy Targeting to CD19 for R/R ALL (clinicaltrials.gov)
    P1/2, N=196, Recruiting, The First Affiliated Hospital of Soochow University | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Aug 2024 --> Aug 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    1d
    IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL. (PubMed, Hemasphere)
    In most dual-driver cases, one subtype gene expression signature predominated, consistent with oncogenic hierarchies, but also with the possibility of technical artifacts, which should prompt individual orthogonal validations. IntegrateALL provides an adaptable fully reproducible workflow for molecular B-ALL characterization by systematically integrating genomic drivers and downstream gene regulation.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • PAX5 (Paired Box 5) • DUX4 (Double Homeobox 4)
    1d
    Pediatric sequential organ failure assessment score predicts prognosis in children with acute lymphoblastic leukemia and sepsis: association with early multiple organ dysfunction. (PubMed, Am J Cancer Res)
    Children with ALL complicated by sepsis, characterized by bloodstream infection, pulmonary infection, multiple site infection, and intermediate-to-high-risk subtypes, have a higher risk of death upon admission to the PICU. Leukemia remission status, 24-hour lactate clearance, inflammatory response, organ function, and respiratory function indicators within 48 hours of PICU admission are closely related to prognosis. Multidimensional indicators combined with a clinical scoring system can help identify high-risk children early and optimize the timing of PICU intervention, thereby improving prognosis.
    Journal
    |
    IL6 (Interleukin 6)
    1d
    Rare NUP98::SETBP1 fusion transcript in a refractory adult T-cell lymphoblastic lymphoma. (PubMed, Am J Cancer Res)
    To our knowledge, this is the first report of the translocation involving NUP98 and SETBP1 genes in T-LBL. It is necessary to collect additional cases and conduct carefully designed experiments to establish the recurrence of this fusion in other T-LBL cohorts and confirm its role as a novel oncogenic rearrangement in T-LBL, providing a basis for managing such patients.
    Journal
    |
    NUP98 (Nucleoporin 98 And 96 Precursor 2) • SETBP1 (SET Binding Protein 1)
    2d
    A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=26, Not yet recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P2 --> P1/2 | Initiation date: Mar 2026 --> Jun 2026
    Phase classification • Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    2d
    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial • IO biomarker
    |
    CD19 (CD19 Molecule)
    3d
    The INFLUENCE Trial: Improve CAR T cell therapy by optimizing fludarabine exposure (2025-523096-34-00)
    P2/3, N=20, Not yet recruiting, Prinses Maxima Centrum voor Kinderoncologie B.V.
    New P2/3 trial
    |
    fludarabine IV
    4d
    Seasonal variation in childhood acute lymphoblastic leukemia, but not in acute myeloid leukemia, or brain tumors - A Swedish population-based study. (PubMed, Cancer Epidemiol)
    These findings support a role for seasonal triggers in ALL and warrant further investigation in larger, genetically stratified cohorts.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6)
    4d
    Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. (PubMed, Clin Cancer Res)
    These findings highlight genomic context in shaping BH3 mimetic responses and point to rational combination of this class of drugs with anti-leukemic agents such as asparaginase.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
    |
    dasatinib • AZD4320
    5d
    Semaphorin 4D (CD100) expression as a predictor for the response to induction therapy in pediatric patients with B-acute lymphoblastic leukemia. (PubMed, Eur J Pediatr)
     PBMCs' Sema4D expression can be considered a potential marker for predicting the response to induction therapy in pediatric patients with B-ALL. So, it may serve to optimize treatment decisions for those patients.
    Journal
    |
    SEMA4D (Semaphorin 4D)
    5d
    Dual-trigger model of CD20 escape: NONO regulation and cryptic splicing induced by transcript overload in pediatric B-ALL. (PubMed, Front Immunol)
    Together, these findings are consistent with a model in which NONO expression and transcript-level dynamics of MS4A1 are associated with CD20 heterogeneity in pediatric B-ALL. These observations may contribute to understanding variability in CD20 expression and antigen availability in pediatric B-ALL.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • MS4A1 (Membrane Spanning 4-Domains A1) • NONO (Non-POU Domain Containing Octamer Binding)
    |
    CD20 positive
    6d
    MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    zorpocabtagene autoleucel (MB-CART 19.1)